MDSC: Markers, development, states, and unaddressed complexity DOI Creative Commons
Samarth Hegde, Andrew M. Leader, Miriam Mérad

et al.

Immunity, Journal Year: 2021, Volume and Issue: 54(5), P. 875 - 884

Published: May 1, 2021

Language: Английский

The hallmarks of successful anticancer immunotherapy DOI Open Access
Lorenzo Galluzzi, Timothy A. Chan, Guido Kroemer

et al.

Science Translational Medicine, Journal Year: 2018, Volume and Issue: 10(459)

Published: Sept. 19, 2018

Various features of the tumor and immune system influence success immunotherapy.

Language: Английский

Citations

493
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors DOI Creative Commons

Rebekka Weber,

Viktor Fleming,

Xiaoying Hu

et al.

Frontiers in Immunology, Journal Year: 2018, Volume and Issue: 9

Published: June 11, 2018

Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the existing anti-tumor immune response by preventing inhibition of T cells tumor cells. Antibodies targeting two negative pathways, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and death-ligand (PD-L1), have been approved first patients with melanoma, squamous non-small lung (NSCLC), renal carcinoma. Clinical trials are ongoing verify efficiency these antibodies other types evaluate strategies block molecules. However, a number do not respond this treatment possibly due profound immunosuppression, which is mediated partly myeloid-derived suppressor (MDSC). This heterogeneous population immature myeloid can strongly inhibit activities NK stimulate regulatory (Treg), leading progression. Moreover, MDSC contribute patient resistance inhibition. Accumulating evidence demonstrates that frequency immunosuppressive function in be as predictive marker therapy response. review focuses on role provides an analysis combination together ICI improve their therapeutic patients.

Language: Английский

Citations

474
Monocyte heterogeneity and functions in cancer DOI Creative Commons
Claire Olingy, Huy Q. Dinh, Catherine C. Hedrick

et al.

Journal of Leukocyte Biology, Journal Year: 2019, Volume and Issue: 106(2), P. 309 - 322

Published: Feb. 18, 2019

Abstract Monocytes are innate immune cells of the mononuclear phagocyte system that have emerged as important regulators cancer development and progression. Our understanding monocytes has advanced from viewing these a homogenous population to heterogeneous display diverse responses different stimuli. During cancer, monocyte subsets perform functions contribute both pro- antitumoral immunity, including phagocytosis, secretion tumoricidal mediators, promotion angiogenesis, remodeling extracellular matrix, recruitment lymphocytes, differentiation into tumor-associated macrophages dendritic cells. The ability evade recognition clearance requires protumoral signals outweigh ongoing attempts by host prevent tumor growth. This review discusses current heterogeneity during homeostasis, highlights in progression, describes monocyte-targeted therapeutic strategies for treatment.

Language: Английский

Citations

468
TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy DOI Creative Commons
Martina Molgora, Ekaterina Esaulova, William Vermi

et al.

Cell, Journal Year: 2020, Volume and Issue: 182(4), P. 886 - 900.e17

Published: Aug. 1, 2020

Language: Английский

Citations

468
MDSC: Markers, development, states, and unaddressed complexity DOI Creative Commons
Samarth Hegde, Andrew M. Leader, Miriam Mérad

et al.

Immunity, Journal Year: 2021, Volume and Issue: 54(5), P. 875 - 884

Published: May 1, 2021

Language: Английский

Citations

465